Cybin
| Cybin IRL | |
|---|---|
| 成立 | 2019年 |
| 總部 | 加拿大多伦多 |
| 产业 | 制药产业 |
| 网站 | cybin |
Cybin IRL是一家加拿大制药公司，专攻迷幻药物的开发[1][2][3]。
产品
[编辑]参考文献
[编辑]- ^ Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L. The Therapeutic Potential of Psilocybin. Molecules. May 2021, 26 (10): 2948. PMC 8156539
. PMID 34063505. doi:10.3390/molecules26102948 .
- ^ Aday, Jacob S.; Barnett, Brian S.; Grossman, Dan; Murnane, Kevin S.; Nichols, Charles D.; Hendricks, Peter S. Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry. Psychedelic Medicine. 1 September 2023, 1 (3): 150–165. ISSN 2831-4425. PMC 11661494 . doi:10.1089/psymed.2023.0013.
Cybin is currently launching a pilot study of a psilocybin analogue that may produce psychoactive effects for only 4 hours.
- ^ Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discov Today. December 2023, 28 (12): 103818. PMID 37925136. doi:10.1016/j.drudis.2023.103818.
